Efficacy of valproic acid for retinitis pigmentosa patients: A pilot study

Clinical Ophthalmology

Volumn 10, Issue , 2016, Pages 1375-1384

  Iraha, Satoshi ^a,b,c,d,e   Hirami, Yasuhiko ^a,b   Ota, Sachiko ^a,b   Sunagawa, Genshiro A ^c   Mandai, Michiko ^a,b,c   Tanihara, Hidenobu ^e   Takahashi, Masayo ^a,b,c,d   Kurimot, Yasuo ^a,b  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c Laboratory for Evolutionary Morphology Center for Developmental Biology   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Clinical trial; Retina; Retinitis pigmentosa; Valproic acid

Indexed keywords

VALPROIC ACID;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD BIOCHEMISTRY; BLOOD CELL COUNT; BLURRED VISION; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERVENTION STUDY; JAPANESE (PEOPLE); MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; RETINITIS PIGMENTOSA; SIDE EFFECT; STOMATITIS; VISUAL ACUITY; VISUAL FIELD;

EID: 84982685092     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S109995     Document Type: Article

References (31)

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006; 368(9549):1795-1809
2. Gregory-Evans K, Pennesi ME, Weleber RG. Retinitis pigmentosa and allied disorders. In: Ryan SJ, editor. RETINA. 5th ed. Philadelphia, PA: SAUNDERS; 2013:761-835
3. Noorwez SM, Ostrov DA, McDowell JH, Krebs MP, Kaushal S. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci. 2008;49(7):3224-3230
4. Clemson CM, Tzekov R, Krebs M, Checchi JM, Bigelow C, Kaushal S. Therapeutic potential of valproic acid for retinitis pigmentosa. Br J Ophthalmol. 2011;95(1):89-93
5. van Schooneveld MJ, van den Born LI, van Genderen M, Bollemeijer JG. The conclusions of Clemson et al concerning valproic acid are premature. Br J Ophthalmol. 2011;95(1):153
6. Sandberg MA, Rosner B, Weigel-DiFranco C, Berson EL. Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. Br J Ophthalmol. 2011;95(5):744
7. Sisk RA. Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. Br J Ophthalmol. 2012;96(8):1154-1155
8. Bhalla S, Joshi D, Bhullar S, Kasuga D, Park Y, Kay CN. Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. Br J Ophthalmol. 2013;97(7):895-899
9. Shanmugam PM, Minija CK, Ramanjulu R, Tekwani P, Saxena M. Effect of short-term oral valproic acid on vision and visual field in retinitis pigmentosa. Ophthalmol Ther. 2012;1(1):6
10. Kumar A, Midha N, Gogia V, Gupta S, Sehra S, Chohan A. Efficacy of oral valproic acid in patients with retinitis pigmentosa. J Ocul Pharmacol Ther. 2014;30(7):580-586
11. Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol. 2009;2(1):95-109
12. Dragunow M, Greenwood JM, Cameron RE, et al. Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience. 2006;140(4):1149-1156
13. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry. 2009;14(1):51-59
14. Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci U S A. 2004;101(47): 16659-16664
15. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem. 2001;276(34): 31674-31683
16. Piao CH, Kondo M, Tanikawa A, Terasaki H, Miyake Y. Multifocal electroretinogram in occult macular dystrophy. Invest Ophthalmol Vis Sci. 2000;41(2):513-517
17. Berson EL, Rosner B, Weigel-DiFranco C, Dryja TP, Sandberg MA. Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci. 2002;43(9): 3027-3036
18. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for Xlinked retinitis pigmentosa. Am J Ophthalmol. 2004;137(4):704-718
19. Rotenstreich Y, Belkin M, Sadetzki S, et al. Treatment with 9-cis β-carotene-rich powder in patients with retinitis pigmentosa: a randomized crossover trial. JAMA Ophthalmol. 2013;131(8):985-992
20. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111(6):761-772
21. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004;122(9):1306-1314
22. Gidal BE, Pitterle ME, Spencer NW, Maly MM. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther. 1995; 20(4):215-219
23. Sriboonruang T, Panomvana D, Chamchitchun S, Silpakit O. The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. J Clin Psychopharmacol. 2011; 31(1):115-119
24. Cloyd JC, Dutta S, Cao G, et al; Depacon Study Group. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003;53(1-2):19-27
25. Stasheff SF, Shankar M, Andrews MP. Developmental time course distinguishes changes in spontaneous and light-evoked retinal ganglion cell activity in rd1 and rd10 mice. J Neurophysiol. 2011;105(6): 3002-3009
26. Stasheff SF. Emergence of sustained spontaneous hyperactivity and temporary preservation of OFF responses in ganglion cells of the retinal degeneration (rd1) mouse. J Neurophysiol. 2008;99(3):1408-1421
27. Kimura A, Guo X, Noro T, et al. Valproic acid prevents retinal degeneration in a murine model of normal tension glaucoma. Neurosci Lett. 2015; 588:108-113
28. Sorri I, Rissanen E, Mantyjarvi M, Kalviainen R. Visual function in epilepsy patients treated with initial valproate monotherapy. Seizure. 2005; 14(6):367-370
29. Ozkul Y, Gurler B, Uckardes A, Bozlar S. Visual functions in epilepsy patients on valproate monotherapy. J Clin Neurosci. 2002;9(3): 247-250
30. Verrotti A, Lobefalo L, Priolo T, et al. Color vision in epileptic adolescents treated with valproate and carbamazepine. Seizure. 2004;13(6): 411-417
31. Verrotti A, Lobefalo L, Tocco AM, et al. Color vision and macular recovery time in epileptic adolescents treated with valproate and carbamazepine. Eur J Neurol. 2006;13(7):736-741.